Anti-CTLA-4 immunotherapy has been investigated for the treatment of HNSCC, with or without additional immune checkpoint inhibitors (anti-PD-1, anti-PDL1) or radiotherapy (reviewed in (12, 74). The gene discussed is CTLA4; the disease is head and neck squamous cell carcinoma.